[HTML][HTML] SARS-CoV-2 B. 1.617. 2 Delta variant replication and immune evasion
The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
was first identified in the state of Maharashtra in late 2020 and spread throughout India, …
was first identified in the state of Maharashtra in late 2020 and spread throughout India, …
[HTML][HTML] Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity
…, J Choi, E Madissoon, KB Meyer, P Mlcochova… - Nature, 2022 - nature.com
The SARS-CoV-2 Omicron BA.1 variant emerged in 2021 1 and has multiple mutations in its
spike protein 2 . Here we show that the spike protein of Omicron has a higher affinity for …
spike protein 2 . Here we show that the spike protein of Omicron has a higher affinity for …
[HTML][HTML] SARS-CoV-2 evolution during treatment of chronic infection
…, A Jahun, M Hosmillo, C Rees-Spear, P Mlcochova… - Nature, 2021 - nature.com
The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
critical for virus infection through the engagement of the human ACE2 protein 1 and is a major …
critical for virus infection through the engagement of the human ACE2 protein 1 and is a major …
[PDF][PDF] Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7
…, G Gallo, N Thakur, DA Collier, P Mlcochova… - Cell reports, 2021 - cell.com
We report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike ΔH69/V70
in multiple independent lineages, often occurring after acquisition of receptor binding motif …
in multiple independent lineages, often occurring after acquisition of receptor binding motif …
[HTML][HTML] FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
…, P Curley, H Pertinez, S Forrest, P Mlcochova… - Nature, 2023 - nature.com
Preventing SARS-CoV-2 infection by modulating viral host receptors, such as angiotensin-converting
enzyme 2 (ACE2) 1 , could represent a new chemoprophylactic approach for …
enzyme 2 (ACE2) 1 , could represent a new chemoprophylactic approach for …
[HTML][HTML] Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation
…, A Jahun, M Hosmillo, C Rees-Spear, P Mlcochova… - MedRxiv, 2020 - ncbi.nlm.nih.gov
SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE2, and amino
acid variation in Spike is increasingly appreciated. Given both vaccines and therapeutics …
acid variation in Spike is increasingly appreciated. Given both vaccines and therapeutics …
Expression of glutamate carboxypeptidase II in human brain
…, C Bařinka, K Hlouchova, A Vicha, P Mlčochová… - Neuroscience, 2007 - Elsevier
… Author links open overlay panel P. Šácha a b , J. Zámečník c , C. … Mlčochová a b , I.
Hilgert e , T. Eckschlager d , J. … Tsukamoto, P. Majer, RJ Miller, AL Monti, RP Roos …
Hilgert e , T. Eckschlager d , J. … Tsukamoto, P. Majer, RJ Miller, AL Monti, RP Roos …
[HTML][HTML] SARS-CoV-2 B. 1.617. 2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough
… Current vaccines were designed to target the B.1, Wuhan-1 virus, and the emergence of
variants with reduced susceptibility to vaccines such as B.1.351 and P.1 has raised fears for …
variants with reduced susceptibility to vaccines such as B.1.351 and P.1 has raised fears for …
[HTML][HTML] The HUSH complex is a gatekeeper of type I interferon through epigenetic regulation of LINE-1s
…, CHC Tie, PA Gould, P Mlcochova… - Nature …, 2020 - nature.com
… test p-value of shMPP8/shControl from DESeq2). See dataset 3 in Source data for all exact p
… closer than randomized genes (p = 0.001, where a one-sided p value was calculated as (1+ …
… closer than randomized genes (p = 0.001, where a one-sided p value was calculated as (1+ …
Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration
RK Gupta, P Mlcochova… - Proceedings of the …, 2009 - National Acad Sciences
Tetherin is an IFN-inducible restriction factor that inhibits HIV-1 particle release in the
absence of the HIV-1 countermeasure, viral protein U (Vpu). Although ubiquitous in HIV-1 and …
absence of the HIV-1 countermeasure, viral protein U (Vpu). Although ubiquitous in HIV-1 and …